ArticleRevista da Associacao Medica Brasileira (1992)2026
Immunoglobulin G and neutralizing antibody response after CoronaVac.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the kinetics of immunoglobulin G and neutralizing antibody responses following vaccination with CoronaVac in healthcare professionals.
methodsA cohort of 35 healthcare professionals was recruited, and blood samples were collected to assess immunoglobulin G detection and neutralizing antibodies against severe acute respiratory syndrome coronavirus 2.
resultsImmunoglobulin G seroconversion peaked at D30 (68.2%, 15/22), followed by stabilization at D48 and D90. Logistic regression confirmed a significant association between time post-vaccination and seroconversion (p=0.0043). Neutralizing antibody analysis showed a stable detection rate for Nab V1 (Wuhan and B.1.1.7) between D48 and D90 (p>0.9999), while Nab V2 (B.1.351 and P.1) remained consistently lower. Among immunoglobulin G-positive individuals, 92.3% (12/13) had neutralizing antibodies at D48, decreasing to 42.8% (6/14) at D90.
conclusionCoronaVac effectively induces immunoglobulin G seroconversion, peaking at D30. However, neutralizing responses to emerging variants were lower, suggesting the need for booster doses to maintain immunity. These findings highlight the importance of monitoring vaccine-induced immunity over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.